Not terribly surprising -- and we still need to wait for a full commission vote, but in as few as six weeks' time, Januvia should prepare to compete head to head with Invokana.
The FDA Advisory Panel just voted, 10-5, to recommend that FDA approve this new drug candidate for adults with Type-2 diabetes.
Beware what that portends for Januvia -- and Whitehouse Station. This is now Merck's biggest selling franchise.
Thursday, January 10, 2013
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment